F XII

Blut

Volumn 61, Issue 5, 1990, Pages 258-266

  Fuhrer, G ^a   Gallimore, M J ^b   Heller, W ^b   Hoffmeister, H E ^b  

^a Abteilung f?r Kardiochirurgie   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Activation; Clinical studies; Coagulation; Complement; F XII; F XII (Hageman factor); Fibrinolysis; High molecular weight kininogen; Inhibition; Prekallikrein

Indexed keywords

BLOOD CLOTTING FACTOR 12; PREKALLIKREIN;

BLOOD CLOTTING; COMPLEMENT SYSTEM; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL; REVIEW;

ANIMAL; BLOOD COAGULATION; BLOOD PRESSURE; COMPLEMENT ACTIVATION; FACTOR XII; FACTOR XII DEFICIENCY; FACTOR XIIA; FIBRINOLYSIS; HUMAN;

EID: 0025678919     PISSN: 00065242     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/BF01732874     Document Type: Review

References (148)

1. Effect of slow intravenous administration of endotoxin on blood cells and coagulation in dogs
2. Studies on components of the plasma kallikrein system in plasma samples from normal individuals and patients with septic shock
3. C1 INH concentrate in the therapy of hereditary angioedema
4. Substrates for kinin-releasing enzymes in human plasma
5. Studies on the human plasma kallikrein system: α kallikrein does not directly activate blood neutrophils
6. Activation of the coagulation system in polycythemia vera
7. The interaction of Hageman factor and immune complexes
8. Activation of Hageman factor in solid and fluid phases
9. Activation of plasminogen by human plasma kallikrein
10. Effect of cleavage of the heavy chain of human plasma kallikrein on its functional properties
11. Effects of plasma kallikrein and plasmin on the first component of complement
12. Generation of bradykinin during incubation of hereditary angioedema plasma
13. Inactivation of factor XII active fragment in normal plasma. Predominant role of C1-inhibitor
14. An intrinsic factor XII-prekallikrein-dependent pathway activates the human plasma renin-angiotension system
15. A biochemical abnormality in hereditary angioedema: absence of serum inhibitor of C1-esterase
16. Inhibition of the activation of Hageman factor (factor XII) by platelet factor 4
17. The cleavage and formation of activated Hageman factor by autodigestion and by kallikrein
18. Studies on Hageman factor, plasma prekallikrein, kallikrein “like” activity and kallikrein inhibition in plasmas from normal subjects and clinical material
19. Assay for Hageman factor (factor XII) in human plasma by means of a chromogenic substrate for plasma kallikrein
20. Effects of plasma kallikrein infusions into pigs on haemodynamic and haemostatic variables
21. Effects of plasma kallikrein and bradykinin infusions into pigs on plasma fibrinolytic variables and urinary excretion of thromboxane and prostacyclin metabolites
22. Hereditary angioedema the clinical syndrome and its management
23. Epsilon-aminocaproic acid for hereditary angioedema
24. Studies on synthetic peptide substrates for F XII enzymes
25. Kallikrein inhibitors
26. Studies on components of the plasma kallikrein-kinin system in patients undergoing cardiopulmonary bypass
27. The effects of heparin and aprotinin on the inhibition by plasma of kallikrein, alpha F XIIa and beta F XIIa
28. Studies on the inhibition of plasma kallikrein, C1-esterase and β F XIIa in the presence and absence of heparins
29. Characterization of bovine factor XIIa (activated Hageman factor)
30. Chromogenic peptide substrate assays for determining components of the plasma kallikrein system
31. Changes in plasma levels of prekallikrein, high molecular weight kininogen and kallikrein hinhibitors during lethal endotoxin shock in dogs
32. The purification of a plasma kallikrein with weak plasminogen activator activity
33. Studies on plasma inhibitors of plasma kallikrein using chromogenic peptide substrate assays
34. A direct chromogenic peptide substrate assay for Hageman factor (F XII)
35. TPA levels during cardiopulmonary bypass
36. The effects of plasma kallikrein and beta F XIIa (F XIIf) on blood components circulating in a cardiopulmonary bypass machine
37. Mechanism of activation of the classical pathway of complement by Hageman factor fragment
38. Urate crystal-dependent cleavage of Hageman factor in human plasma and synovial fluid
39. Cold promoted activation of factor VII. III. Relation to the kallikrein system
40. The activation of plasminogen by Hageman factor (F XII) and Hageman factor fragments
41. Rapid fibrinolysis augmented Hageman factor (factor XII) titers and decreased C1 inhibitor titres in women using oral contraceptives
42. The role of surface in the surface-dependent activation of Hageman factor (factor XII)
43. Human factor XII (Hageman factor)
44. Recent advances in the understanding of contact activation reactions
45. The contact phase of blood coagulation
46. Human plasma alpha-2-macroglobulin. An inhibitor of plasma kallikrein
47. Evidence for a new plasma thromboplastin factor. 1. Case report, coagulation studies and physicochemical properties
48. Prourokinase activation in euglobulin fractions
49. Substrates of Hageman factor. 1. Isolation and characterization of human factor XIa (PTA) and inhibition of the activated enzyme by α1-antitrypsin
50. Inhibition of activated Hageman factor (Factor F XIIa) by an inhibitor of the plasminogen activation (PA inhibitor)
51. Effect of elevated C1-esterase inhibitor levels on elastase release in vitro. A proposed model for shock (ECC)
52. Changes in the kallikrein-kinin system after different dose regimen of aprotinin during cardiopulmonary bypass operation
53. Hageman factor fragment inhibitor in corn seeds: purification and characterization
54. In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulphate
55. Deficiency of Hageman factor (factor XII) in patients with nephrotic syndrome
56. Contribution of contact activation factors to urokinase-related fibrinolytic activity in whole human plasma
57. Substrates for plasma kinin forming enzymes in human, dog and rabbit plasma
58. A pre-albumin activator of prekallikrein
59. The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator
60. In vitro studies of the pathogenesis of cold urticaria, cholinergic urticaria and vibrationinduced swelling
61. A prealbumin activator of prekallikrein. II. Appearance of chemotactic activity for human neutrophils by the conversion of prekallikrein to kallikrein
62. Assessment of Hageman factor activation in human plasma: quantitation of activated Hageman factor-C1-inactivator complexes by an enzymelinked differential antibody immunosorbent assay
63. The coagulation-kinin pathway of human plasma
64. The kallikrein-kinin system in inflammation
65. Chromogenic peptide substrate assays in patients with multiple trauma
66. Interaction between the extrinsic and intrinsic systems of fibrinolysis
67. Direct assay of Factor F XIIa in plasma with synthetic chromogenic substrates
68. Activation of human factor XI (plasma thromboplastin antecedent) by factor XIIa (activated Hageman factor)
69. Human platelets and factor XI. Localisation in platelet membranes of factor XI-like activity and its functional distinction from plasma factor XI
70. Identification of prekallikrein and HMW-kininogen as a circulating complex in human plasma
71. Hageman factor substrates. Human plasma prekallikrein: Mechanism of activation by Hageman factor and participation in Hageman factor-dependent fibrinolysis
72. Clotting activities and antigen concentrations of contact factors in kidney disease
73. Pharmacology of hirudin: 100 years after the first report of the anticoagulant agent in medicinal leeches
74. Plasma kallikrein and Hageman factor in gram-negative bacteremia
75. The role of Hageman factor in disseminated intravascular coagulation induced by sepsis, neoplasia or liver disease
76. Inactivation of human plasma kallikrein and FF XIa by protein C inhibitor
77. The relationship between the contact system and the protein C pathway
78. Inhibition of serine proteinases by p-carbothoxyphenyl esters of e-guanidino and e-amino caproic acid: Thermodynamic and molecular modeling study
79. Coagulation factor XII (Hageman factor) Washington DC: Inactive factor XIIa results from Cys-571-Ser substitution
80. Activation of Hageman factor and prekallikrein and generation of kinin by various microbial proteinases
81. Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins)
82. The contact phase of blood coagulation: clotting factors XI and XII, their isolation and interaction
83. Consumption of Hageman factor activity in the generalized schwartman reaction induced by liquoid. Its prevention by inhibition of Hageman factor activation
84. Purification and properties of human low molecular weight kininogen
85. Studies on human kininogen I. Isolation, characterization and cleavage by plasma kallikrein of high molecular weight kininogen
86. Role du facteur contact (facteur Hageman) dans la fibrinolyse
87. On the role of the C1-esterase inhibitor in cold urticaria
88. The contact system
89. Detection of activation of the contact system of coagulation in vitro and in vivo: Quantitation of activated Hageman factor-C1 inhibitor and kallikrein-C1 inhibitor complexes by specific radioimmunoassays
90. Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: the participation of Hageman factor and additional cofactors
91. Hereditary angioneurotic edema
92. Chemistry and biology of the kallikrein-kinin system. Proteases and biological control
93. Effect of heparin on the inactivation of human F XIIa by antithrombin III
94. Neutrophil secretion during blood coagulation: Evidence for prekallikrein independent pathway
95. Activation of F VII by Hageman factor fragments
96. A quarter century with Mr Hageman
97. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction from plasma
98. The conversion of Cls to C1 esterase by plasmin and trypsin
99. Role of Hageman factor in the initiation of clotting by glass
100. Surface mediated reactions
101. Structural changes accompanying enzymatic activation of human Hageman factor
102. The relationship of structure and function in human Hageman factor. The association of enzymatic binding activities with separate regions of the molecule
103. Multiple forms of active Hageman factor (coagulation factor XII) produced during contact activation
104. Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma
105. Bradykinin, hypotensive and smooth muscle stimulator released from plasma globulin by snake venoms and trypsin
106. The effect of aprotinin on need for blood transfusion after repeat open-heart surgery
107. Defective activation of clotting, fibrinolytic and permeability enhancing systems in human Fletcher trait plasma
108. Radioimmune assay of human Hageman factor (factor XII)
109. Molecular heterogeneity of Hageman trait (factor XII deficiency): evidence that 2 of 49 cases are cross-reacting material positive (CRM+)
110. Activation of the kallikrein-kinin system in premature infants with respiratory distress syndrome (RDS)
111. Major inhibitors of the contact phase coagulation factors
112. Prekallikrein activation and high molecular weigh kininogen consumption in hereditary angioedema
113. Protection by recombinant α1-antitrypsin Ala 357 Arg 358 against arterial hypotension induced by factor XII fragment
114. Platelet C1 inhibitor. A secreted alpha-granule protein
115. Contact activation and its abnormalities
116. Inositolphospholipid-accelerated activation of prekallikrein by activated F XII and its inhibition by β2-glycoprotein
117. Parameters of the kallikrein-kinin, coagulation and fibrinolytic systems as early indicators of kidney transplant rejection
118. Alpha-1-antitrypsin-Pittsburg. A potent inhibitor of human F XIa, kallikrein and factor XIIf
119. Inhibition of contact activation by platelet factor 4
120. Initiation of plasma prorenin activation by Hageman factor-dependent conversion of plasma prekallikrein to kallikrein
121. Evidence for the participation of both activated factor XII and activated factor XI in cold-promoted activation of factor VII
122. Angiotensin-converting enzyme and the regulation of vasoactive peptides
123. New data on Hageman factor and plasma thromboplastin anticedent: the role of “contact” in the initial phase of blood coagulation
124. Inhibition of activated factor XII by antithrombin III-heparin cofactor
125. A new assay for the determination of factor XII in plasma using a chromogenic substrate and a selective inhibitor of plasma kallikrein
126. Activation of factor XII by dextran sulphate. The basis of an assay for factor XII
127. Association of F XI and high molecular weight kininogen in human plasma
128. Behaviour of the contact phase of blood coagulation in the adult respiratory distress syndrome (ARDS)
129. Inactivation and binding of human plasma kallikrein by antithrombin III
130. Assay of total Factor XII in plasma with a chromogenic substrate
131. Purified plasma F XIIa aggregates human neutrophils and causes degranulation
132. Human neutrophil degranulation during extracorporeal circulation
133. Formation of C1s-C1 inhibitor, kallikrein-C1-inhibitor and plasma-α2-plasmin inhibitor complexes during cardiopulmonary bypass
134. Fitzgerald factor: a hitherto unrecognized clotting factor
135. Contribution of human platelets to the proteolytic activation of blood coagulation factors XII and XI
136. Chemotactic activity generated from the fifth component of complement by plasma kallikrein in the rabbit
137. Kallikrein-bradykinin system in chronic alcoholic liver disease
138. Biochemistry and biology of components of the plasma kinin-forming system
139. Plasma prekallikrein: Isolation, characterization and mechanism of activation
140. Spontaneous activation of the first component of human complement (cl) by an intramolecular autocatalytic mechnaism
141. Purified human plasma kallikrein does not stimulate but primes neutrophils for superoxide production